Evidence map›Paper›PMID 40790328›Full record

ArticleScientific reports2025

Chimeric SF-25 monoclonal antibody as a targeted therapy for SLC3A2 in adult T-cell leukemia/lymphoma.

Shinsuke Suzuki, Xiao-Yan Lin, Shuichi Hanada, Kimiharu Uozumi, Maki Otsuka, Satsuki Owatari, Koichi Haraguchi, Makoto Yoshimitsu, Kenji Ishitsuka, Hiroshi Takahashi

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Shinsuke Suzuki *Center for Cancer Advanced Therapy, Kagoshima University Hospital, Kagoshima, Japan.
Xiao-Yan Lin *Department of Medical Oncology, Fujian Medical University Union Hospital, Fuzhou, People's Republic of China.
Shuichi HanadaDepartment of Hematology, National Hospital Organization Kagoshima Medical Center, 8-1 Shiroyama, Kagoshima, 892-0853, Japan. hanadas1949@icloud.com.
Kimiharu UozumiDepartment of Medical Oncology, National Hospital Organization Kagoshima Medical Center, Kagoshima, Japan.
Maki OtsukaDepartment of Hematology, National Hospital Organization Kagoshima Medical Center, 8-1 Shiroyama, Kagoshima, 892-0853, Japan.
Satsuki OwatariDepartment of Hematology, National Hospital Organization Kagoshima Medical Center, 8-1 Shiroyama, Kagoshima, 892-0853, Japan.
Koichi HaraguchiDepartment of Hematology, National Hospital Organization Kagoshima Medical Center, 8-1 Shiroyama, Kagoshima, 892-0853, Japan.
Makoto YoshimitsuDepartment of Hematology and Rheumatology, Kagoshima University Hospital, Kagoshima, Japan.
Kenji IshitsukaDepartment of Hematology and Rheumatology, Kagoshima University Hospital, Kagoshima, Japan.
Hiroshi TakahashiVeritas Medical Partners Azabu Clinic, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The SF-25 antigen (SF-25 Ag), which functions as the amino acid transporter solute carrier family 3 member 2 (SLC3A2), is essential for regulatory T (Treg) cell maintenance and is highly expressed in adult T-cell leukemia/lymphoma (ATL) cells. We analyzed SF-25 Ag expression in CD4+peripheral blood lymphocytes (PBLs) from 28 ATL patients, 52 healthy human T-lymphotropic virus 1 (HTLV-1) carriers, and eight non-infected individuals. Inverse polymerase chain reaction was used to detect monoclonal integration of HTLV-1 proviral DNA. The median (interquartile range) percentages of SF-25 Ag-positive PBLs in acute, chronic, and smoldering ATL were 54.9% (23.9-62.9), 34.9% (23.8-41.9), and 22.1% (8.4-28.5), respectively, which were significantly higher than those in HTLV-1 carriers (0.8% [0.5-1.0]) and non-infected subjects (0.4% [0.3-0.4]) (P < 0.001). Magnetic sorting isolated SF-25 Ag-positive cells, which showed monoclonal HTLV-1 integration, unlike SF-25 Ag-negative cells. Moreover, culture supernatant from healthy donor PBLs stimulated with a murine-human chimeric SF-25 monoclonal antibody (c-SF-25 Mab) induced apoptosis in SF-25 Ag-positive ATL cells. These findings suggest that c-SF-25 Mab, by targeting SLC3A2, may offer a specific therapeutic approach for ATL by eliminating malignant cells while sparing normal tissue.

Indexed as

Amino Acid Transport Systems, NeutralAntibodies, MonoclonalLeukemia-Lymphoma, Adult T-CellAdultAgedAnimalsCD4-Positive T-LymphocytesFemaleFusion Regulatory Protein 1, Heavy ChainHumansHuman T-lymphotropic virus 1MaleMiddle AgedAmino Acid Transport Systems, NeutralAntibodies, MonoclonalFusion Regulatory Protein 1, Heavy ChainSLC3A2 protein, humanAdult T-cell leukemia/lymphomac-SF-25 MabHTLV-1Magnetic cell sortingSF-25 AgSLC3A2

Identifiers

PMID40790328
PMCPMC12340079

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.